Novo Nordisk stock plunges 20% after cutting sales and profit forecasts for weight-loss drug Wegovy and diabetes treatment Ozempic. Operating profit growth lowered to 10%-16%. Competition and slower market expansion cited for weaker outlook. Hims & Hers Health and Eli Lilly also down. Novo Nordisk CEO replaced amidst ongoing challenges.

Read more at Yahoo Finance: Novo Nordisk stock crashes after company cuts sales, profit outlook on weight loss drug competition